The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index; none of the 5 sources its claims cite is checked for support yet.
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor
Open accessAbstract
Histone deacetylases (HDACs) are a family of enzymes involved in the regulation of gene expression, DNA repair, and stress response. These processes often are altered in tumors, and HDAC inhibitors have had pronounced antitumor activity with promising results in clinical trials. Here, we report the crystal structure of human HDAC8 in complex with a hydroxamic acid inhibitor. Such a structure of a eukaryotic zinc-dependent HDAC has not be described previously. Similar to bacterial HDAC-like protein, HDAC8 folds in a single α/β domain. The inhibitor and the zinc-binding sites are similar in both proteins. However, significant differences are observed in the length and structure of the loops surrounding the active site, including the presence of two potassium ions in HDAC8 structure, one of which interacts with key catalytic residues. CD data suggest a direct role of potassium in the fold stabilization of HDAC8. Knockdown of HDAC8 by RNA interference inhibits growth of human lung, colon, and cervical cancer cell lines, highlighting the importance of this HDAC subtype for tumor cell proliferation. Our findings open the way for the design and development of selective inhibitors of HDAC8 as possible antitumor agents.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
The paper reports the crystal structure of human HDAC8, a eukaryotic zinc-dependent histone deacetylase, in complex with a hydroxamic acid inhibitor, revealing a single α/β domain, a pentacoordinated active-site Zn²⁺, and two bound K⁺ ions. It also shows that HDAC8 has a distinct inhibitor profile and that siRNA knockdown of HDAC8 inhibits proliferation of A549, HeLa, and HCT116 tumor cell lines.
Key findings
- The HDAC8 monomer folds as a single compact α/β domain with a central eight-stranded parallel β-sheet and 11 α-helices; the crystal contains a head-to-head dimer burying ≈1,300 Ų, but size-exclusion chromatography and light scattering are compatible with a monomer in solution. The active-site Zn²⁺ is pentacoordinated by Asp-178, His-180, Asp-267, and the hydroxamate inhibitor.
- Two K⁺ sites were identified: site 1 is 7.0 Å from the zinc site and site 2 is 15 Å from site 1, with peaks of 19σ and 13σ, respectively. K⁺ site 1 contacts backbone carbonyls of Asp-178 and His-180, whose side chains coordinate zinc. CD spectroscopy showed a melting midpoint of ≈35.5°C in NaCl versus ≈41°C in KCl.
- HDAC8 inhibition differed from HDAC1 and HDAC3: IC₅₀ values for HDAC8/HDAC1/HDAC3 were TSA 490/1.5/0.6 nM, SAHA 4,000/119/106 nM, Compound 1 175.5/86.0/44 nM, MS27-275 >10,000/185/201 nM, and apicidin >1,000/2/0.7 nM. Compound 1 showed relatively similar potency across all three enzymes (<4-fold differences).
- Two HDAC8 siRNAs inhibited proliferation in A549, HeLa, and HCT116 cells; an Eg5 siRNA gave comparable growth inhibition, whereas an unrelated Luc siRNA had no effect.
Methods
- Human HDAC8 was expressed and purified, then crystallized after incubation of 130 μM HDAC8 with a 6.7 molar excess of inhibitor for 1 h at room temperature. Crystals were grown by sitting-drop vapor diffusion; data were collected at 100 K using synchrotron radiation.
- The structure was solved by molecular replacement using a truncated homology model of HDAC8 residues 63–320 based on the HDLP–TSA structure (PDB 1C3R), and refined to 2.5 Å with final R and R_free of 0.21 and 0.25.
- CD spectroscopy measured thermal unfolding in KCl- or NaCl-containing buffers. siRNA transfection and cell-growth assays were performed in A549, HeLa, and HCT116 cells; HDAC inhibition assays tested HDAC1, HDAC3, and HDAC8 against a panel of inhibitors.
Limitations
- The paper states no formal limitations section. It notes that the crystal dimer is mediated by the inhibitor and is unlikely to occur in solution, and that the relevance of potassium-binding site 2 for catalytic activity is not obvious from the structure.
- Evident from the text: the structural conclusions come from one 2.5-Å crystal form; potassium-binding site 1 was identified at 75 mM K⁺ in the crystallization drop, lower than the intracellular physiological value of ≈150 mM; and the RNAi proliferation data are limited to three human tumor cell lines with no in vivo results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 5 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Potassium-binding site 2 ([Fig. 6*B*](#fig6)) is formed by the main-chain carbonyl oxygen of residues Phe-189, Thr-192, Val-195, and Tyr-225 and two water molecules.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compound 1, an aryl hydroxamic acid identified by screening a collection of small molecules, instead showed relatively similar potencies (<4-fold differences) on all tested proteins.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the active site, the van der Waals surface of the enzyme reveals an ≈12-Å-deep, narrow pocket likely to accommodate the acetylated lysine during the catalytic reaction.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Potassium-binding site 1 is directly connected with the zinc-binding site, because the K+ ion is coordinated by the main-chain carbonyl oxygens of Asp-178 and His-180, whose side chains are involved in zinc chelation ([Fig. 4*A*](#fig4)).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“each capping group interacts with protein residues Pro-273 and Tyr-306 of the opposite molecule, forming an extensive hydrophobic sandwich”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additional van der Waals interactions occur between the linker region and the side chain of Met-274 and the main chain of Gly-151.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At site 1, the K+ ion is hexacoordinated by six oxygen ligands from Asp-176 (main-chain carbonyl oxygen and Oδ1), Asp-178 (main-chain carbonyl oxygen), His-180 (main-chain carbonyl oxygen), Ser-199 (Oγ), and Leu-200 (main-chain carbonyl oxygen), arranged in a distorted octahedral geometry ([Fig. 6*B*](#fig6)).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The two molecules are essentially identical (rms deviation 0.34 Å for the Cα trace)”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The twisted β-sheet (topology β2, -1, -3, -8, -7, -4, -5, and -6) is flanked by five helices on one side (topology α2, -10, -9, -8, and -11) and three helices (topology α5, -6, and -7) on the other.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, HDAC8 shows a more restricted inhibition pattern than other class I enzymes”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 6
- It may state two separate claims as one. 22
- The quote only partly states this claim. 1
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Residues at potassium-binding site 1 are conserved in all zinc-dependent HDACs, with the exception of Leu-200, which can be substituted with Phe (HDAC1, -2, and -3) or Trp (HDAC10).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Each molecule binds one Zn2+ ion and two K+ ions.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“the loop region featuring the equivalent of Pro-22 from HDLP (Ala-32 in HDAC8), a residue that interacts with the capping group of TSA inhibitor ([11](#ref11)), is shorter in HDAC8, and therefore this interaction is not possible ([Fig. 2*C*](#fig2))”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
What the sources say
- Not checked yetcites [11] Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R. & Pavletich, N. P. (1999) Nature 401**,** 188–193. [[DOI](https://doi.org/10.1038/43710)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/10490031/)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nature&volume=401&publication_year=1999&pages=188&pmid=10490031&doi=10.1038/43710&)] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar to bacterial HDAC-like protein, HDAC8 folds in a single α/β domain.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Abstract
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“All residues contacting the linker are conserved except for Met-274, which is a Leu in all other class I and II HDACs with the exception of HDAC10, which has a Glu in this position.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“including the presence of two potassium ions in HDAC8 structure, one of which interacts with key catalytic residues.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most strikingly, the loop 332–345, part of the long extended linker between α10 and -11, is 10 residues shorter than that observed in HDLP, leaving the active site less shielded from one side”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The two potassium-binding sites are placed on the same face of the β-sheet and contribute equally to anchoring helix α7 and its loops to the central β-sheet ([Fig. 6*B*](#fig6)).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cyclic linker region of the inhibitor fits in the hydrophobic channel, with its aromatic aryl moiety stacked between side chains of Phe-152 and -208.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“TSA and SAHA, both poor HDAC8 inhibitors ([Table 1](#tbl1))”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Unexpectedly, the structure of HDAC8 reveals K+ ions bound at two sites: Site 1 is in close proximity (7.0 Å) to the zinc-binding site, whereas site 2 is located more toward the periphery of the molecule, 15 Å away from site 1 ([Fig. 6*B*](#fig6)).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Residues forming the two potassium-binding sites come from loops contiguous to helix α7 (Asp-178 and His-180 at site 1; Phe-189 and Thr-192 at site 2) and from strands β4, -5, and -6 (Asp-176, Ser-199, and Leu-200 at site 1; Val-195 and Tyr-225 at site 2).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The authors describe the structure of human HDAC8 with four inhibitors. Their structures are comparable to ours.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Acknowledgments
What the sources say
- Not checked yetcites [21] Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., *et al.* (2004) Structure 7**,** 1325–1334. [[DOI](https://doi.org/10.1016/j.str.2004.04.012)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/15242608/)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Structure&volume=7&publication_year=2004&pages=1325&pmid=15242608&doi=10.1016/j.str.2004.04.012&)]
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the results of size-exclusion chromatography and light-scattering experiments are compatible with a monomeric state for both the apoprotein and the protein–inhibitor complex (data not shown).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The capping group of the inhibitor is oriented in the direction of pocket d, even if this moiety does not interact with the protein but points toward the solvent.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The sequence conservation at this site is somewhat lower than at site 1: Thr-192 is Asp in class II HDACs; Val-195 is different only in HDAC9 (Ile); and Tyr-225 is different only in HDAC10 (Phe).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The presence of K+ in the active site can be expected to influence the catalytic mechanism of the deacetylation reaction in several aspects.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The exchange with Na+ ions, which share with K+ the same external electronic configuration but a remarkably smaller ionic radius, could alter the overall folding of the enzyme, in agreement with the decreased protein stability observed when the protein was purified in the presence of NaCl (data not shown).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Trp-141 is replaced by Leu in HDAC1 and -3, which should leave more space to accommodate this inhibitor and is in line with the increased potency toward HDAC1 and -3.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“By analogy to Ca2+-binding proteins ([20](#ref20)), upon chelation with the cation, the two CO bonds of the Asp-176 side chain no longer should be equivalent, with the bond of the chelating oxygen having more single-bond character and that of the nonchelating oxygen, hydrogen-bonded to His-142, more double-bond character.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
What the sources say
- Not checked yetcites [20] Mizuguchi, M., Nara, M., Kawano, K. & Nitta, K. (1997) FEBS Lett. 417**,** 153–156. [[DOI](https://doi.org/10.1016/s0014-5793(97)01274-x)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/9395095/)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=FEBS%20Lett.&volume=417&publication_year=1997&pages=153&pmid=9395095&doi=10.1016/s0014-5793(97)01274-x&)]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The two sites were identified by strong positive peaks (19 and 13 σ, respectively) in the *F*o – *F*c maps and had typical distances and hexacoordination geometry for potassium binding ([19](#ref19)).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
What the sources say
- Not checked yetcites [19] Harding, M. M. (2002) Acta Crystallogr. D 58**,** 872–874. [[DOI](https://doi.org/10.1107/s0907444902003712)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/11976508/)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Acta%20Crystallogr.%20D&volume=58&publication_year=2002&pages=872&pmid=11976508&doi=10.1107/s0907444902003712&)] source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This finding is in line with the increased potency of TSA and SAHA observed on HDAC1 and -3 with respect to HDAC8.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Data deposition: The coordinates and structure factors have been deposited in the Protein Data Bank, [www.pdb.org](http://www.pdb.org) (PDB ID code 1W22).”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Acknowledgments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“First, its presence increases the positive electrostatic potential in the active site and therefore could contribute to stabilize the oxyanion formed in the transition state of the deacetylation reaction and/or to stabilize the negatively charged acetate product.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The final concentration of K+ ions in the crystallization drop is 75 mM, a value lower than its intracellular physiological value of ≈150 mM, suggesting that the potassium-binding sites could be biologically relevant.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The intracellular physiological K+ concentration is approximately 150 mM.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These chains act as optimal linkers for the hydroxamic acid and the capping group, allowing contacts both at the bottom and the entrance of the pocket.”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is conceivable that structural variability in the loop regions emerging from the conserved core will be found across the entire family of HDACs”
§ Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor > Results and Discussion
Strength:hedged· not yet calibratedTests✗ Asserted: fails✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The authors may not put it forward as true. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper relies on this without support.
No structure of a eukaryotic zinc-dependent HDAC had been described before this study.
“Such a structure of a eukaryotic zinc-dependent HDAC has not be described previously.”
The paper relies on this without support.
The dimeric arrangement seen in the crystal has not been found in solution.
“given that the dimeric arrangement seen in the crystal has not been found in solution”
The paper relies on this without support.
The intracellular physiological K+ concentration is approximately 150 mM.
“a value lower than its intracellular physiological value of ≈150 mM”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Crystal structures of human HDAC8, in complex with different inhibitors, have been reported; they revealed a single α/β-domain with a core eight-stranded parallel β-sheet and 11 α-helices.7, 31, 32”
From HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine (2016) · cites this paper as [7]
In the citing paper
“More generally, HDAC8 affects cell proliferation in different tumor types (Vannini et al., 2004).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Vannini et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
HDAC8 is both described as having Ala and included among enzymes with Pro at the same position
MinorThe paper identifies Ala-32 in HDAC8 as equivalent to Pro-22 in HDLP, then says that all class I and II HDACs except HDAC10 have Pro at that position. HDAC8 is identified elsewhere in the paper as a class I HDAC.
“the equivalent of Pro-22 from HDLP (Ala-32 in HDAC8)”
“A Pro is present in this position in all class I and II HDACs, with the exception of HDAC10, which has an Ile”
Citations
Cites
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,760
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Elective induction versus spontaneous labor after sonographic diagnosis of fetal macrosomia.
Combs, C. A., Singh, N. B., & Khoury, J. C. (1993) · PubMed · Cited by 2,463
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Suzuki, H., Gabrielson, E. W., Chen, W., Anbazhagan, R., van Engeland, M., Weijenberg, M. P., Herman, J. G., & Baylin, S. B. (2002) · Nature Genetics · doi:10.1038/ng892 · Cited by 858
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Histone acetylation and deacetylation in yeast
Kurdistani, S. K., & Grunstein, M. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1075 · Cited by 677
Flagged first, then by citations
Research works printed but not linked: 1
- Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) Structure 7, 1325–1334.
Cited by
Sorted by citations
Items 101–200 of 713
Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate
Sekhavat, A., Sun, J., & Davie, J. (2007) · Biochemistry and Cell Biology · doi:10.1139/o07-145 · Cited by 110
Corminbœuf, C., Hu, P., Tuckerman, M. E., & Zhang, Y. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0600882 · Cited by 108
Hamon, M. A., & Cossart, P. (2011) · Infection and Immunity · doi:10.1128/iai.01243-10 · Cited by 105
Vögerl, K., Ong, N., Senger, J., Herp, D., Schmidtkunz, K., Marek, M., Müller, M., Bartel, K., Shaik, T. B., Porter, N. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01090 · Cited by 104
Ononye, S. N., VanHeyst, M. D., Oblak, E. Z., Zhou, W., Ammar, M. M., Anderson, A. C., & Wright, D. L. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400158k · Cited by 104
Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart
McKinsey, T. A. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.11.009 · Cited by 103
Chemical and structural biology of protein lysine deacetylases
Yoshida, M., Kudo, N., Kosono, S., & Ito, A. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.019 · Cited by 109
Tang, H., Wang, X. S., Huang, X., Roth, B. L., Butler, K. V., Kozikowski, A. P., Jung, M., & Tropsha, A. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800366f · Cited by 101
Chen, P. C., Patil, V., Guerrant, W., Green, P., & Oyelere, A. K. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.050 · Cited by 100
Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases
JONES, P. G., Altamura, S., Francesco, R. D., Gallinari, P., Lahm, A., Neddermann, P., Rowley, M., Serafini, S., & Steinkühler, C. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.02.025 · Cited by 103
Self-citationSmall Molecule Inhibitors of Zinc-dependent Histone Deacetylases
Wagner, F. F., Weïwer, M., Lewis, M. C., & Holson, E. B. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0226-1 · Cited by 99
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors
Sangwan, R., Rajan, R., & Mandal, P. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.073 · Cited by 97
Transcription and beyond: the role of mammalian class I lysine deacetylases
Moser, M., Hagelkrüys, A., & Seiser, C. (2013) · Chromosoma · doi:10.1007/s00412-013-0441-x · Cited by 99
Discovery of histone deacetylase 8 selective inhibitors
Tang, W., Luo, T., Greenberg, E. F., Bradner, J. E., & Schreiber, S. L. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.134 · Cited by 95
Thaler, F., & Mercurio, C. (2013) · ChemMedChem · doi:10.1002/cmdc.201300413 · Cited by 99
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
Witter, D. J., Harrington, P., Wilson, K. J., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., & Miller, T. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.047 · Cited by 93
HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration
Tang, X., Li, G., Su, F., Cai, Y., Shi, L., Meng, Y., Liu, Z., Sun, J., Wang, M., Qian, M., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa039 · Cited by 91
Hooker, J. M., Kim, S. W., Alexoff, D. L., Xu, Y., Shea, C. E., Reid, A. E., Volkow, N. D., & Fowler, J. S. (2009) · ACS Chemical Neuroscience · doi:10.1021/cn9000268 · Cited by 91
Chromatin-remodelling mechanisms in cancer
Lafon-Hughes, L., Tomaso, M. V. D., Méndez-Acuña, L., & Martínez‐López, W. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.01.008 · Cited by 94
Weston, C. E., Krämer, A., Colin, F., Yıldız, Ö., Baud, M. G. J., Meyer‐Almes, F., & Fuchter, M. J. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00148 · Cited by 93
Histone deacetylase inhibitors: Anticancer compounds
Smith, K. T., & Workman, J. L. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.09.008 · Cited by 90
Zhou, L., & Yu, D. C. W. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107205 · Cited by 96
Macrocyclic Histone Deacetylase Inhibitors
Mwakwari, S. C., Patil, V., Guerrant, W., & Oyelere, A. K. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610792232079 · Cited by 90
Arts, J., Angibaud, P. R., Mariën, A., Floren, W., Janssens, B., King, P., Dun, J. V., Janssen, L., Geerts, T., Tuman, R. W., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604025 · Cited by 89
HDAC-mediated control of ERK- and PI3K-dependent TGF-β-induced extracellular matrix-regulating genes
Barter, M. J., Pybus, L. P., Litherland, G. J., Rowan, A. D., Clark, I. M., Edwards, D. R., Cawston, T. E., & Young, D. A. (2010) · Matrix Biology · doi:10.1016/j.matbio.2010.05.002 · Cited by 94
Pontiki, E. A., & Hadjipavlou‐Litina, D. (2010) · Medicinal Research Reviews · doi:10.1002/med.20200 · Cited by 89
Hawk, J. D., Florian, C., & Abel, T. (2011) · Learning & Memory · doi:10.1101/lm.2097411 · Cited by 98
Natural chalcones as dual inhibitors of HDACs and NF-κB
Orlikova, B., Schnekenburger, M., Zloh, M., Golais, F., Diederich, M. F., & Taşdemir, D. (2012) · Oncology Reports · doi:10.3892/or.2012.1870 · Cited by 92
Activation and Inhibition of Histone Deacetylase 8 by Monovalent Cations
Gantt, S. L., Joseph, C. G., & Fierke, C. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033399 · Cited by 87
Thangapandian, S., John, S., Sakkiah, S., & Lee, K. W. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.06.024 · Cited by 87
The Role of the Metabolism of Zinc and Manganese Ions in Human Cancerogenesis
Rozenberg, J. M., Kamynina, М., Sorokin, M., Zolotovskaia, M., Koroleva, E. V., Kremenchutckaya, K., Gudkov, A., Buzdin, A. A., & Borisov, N. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051072 · Cited by 88
Lee, H., Sengupta, N., Villagra, A., Rezai‐Zadeh, N., & Seto, E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01971-05 · Cited by 86
Fluorous‐Based Small‐Molecule Microarrays for the Discovery of Histone Deacetylase Inhibitors
Vegas, A. J., Bradner, J. E., Tang, W., McPherson, O. M., Greenberg, E. F., Koehler, A. N., & Schreiber, S. L. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200703198 · Cited by 86
Histone Deacetylase Inhibitors through Click Chemistry
Shen, J., Woodward, R., Kedenburg, J., Liu, X., Chen, M., Fang, L., Sun, D., & Wang, P. G. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8005355 · Cited by 85
Olsen, C. A., & Ghadiri, M. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900850t · Cited by 85
Histone deacetylase 8 is required for centrosome cohesion and influenza A virus entry
Yamauchi, Y., Boukari, H., Banerjee, I., Sbalzarini, I. F., Horvath, P., & Helenius, A. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002316 · Cited by 84
On the inhibition of histone deacetylase 8
Estiu, G. L., West, N. H., Mazitschek, R., Greenberg, E. F., Bradner, J. E., & Wiest, O. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.080 · Cited by 84
Molecular Insights into Azumamide E Histone Deacetylases Inhibitory Activity
Maulucci, N., Chini, M. G., Micco, S. D., Izzo, I., Cafaro, E., Russo, A., Gallinari, P., Paolini, C., Nardi, M. C., Casapullo, A., et al. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0686256 · Cited by 84
Self-citationHDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Karagiannis, D., & Rampias, T. N. (2021) · Cancers · doi:10.3390/cancers13143575 · Cited by 88
Montero, A., Beierle, J. M., Olsen, C. A., & Ghadiri, M. R. (2009) · Journal of the American Chemical Society · doi:10.1021/ja809508f · Cited by 83
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells
Kang, Y., Nian, H., Rajendran, P., Kim, E., Dashwood, W. M., Pinto, J. T., Boardman, L. A., Thibodeau, S. N., Limburg, P. J., Löhr, C. V., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.422 · Cited by 83
HDAC8 substrates: Histones and beyond
Wolfson, N. A., Pitcairn, C. A., & Fierke, C. A. (2012) · Biopolymers · doi:10.1002/bip.22135 · Cited by 83
Dowling, D., Gattis, S. G., Fierke, C. A., & Christianson, D. W. (2010) · Biochemistry · doi:10.1021/bi1005046 · Cited by 83
Moffat, D. F. C., Patel, S. R., Day, F. A., Belfield, A. J., Donald, A., Rowlands, M., Wibawa, J. I. D., Brotherton, D. H., Stimson, L., Clark, V., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101177s · Cited by 81
Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors
Suzuki, N., Suzuki, T., Ota, Y., Nakano, T., Kurihara, M., Okuda, H., Yamori, T., Tsumoto, H., Nakagawa, H., & Miyata, N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900125m · Cited by 81
Culley, K. L., Wang, H., Barter, M. J., Davidson, R. K., Swingler, T. E., Destrument, A., Scott, J. L., Donell, S. T., Fenwick, S., Rowan, A. D., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37965 · Cited by 80
Trans-regulation of Histone Deacetylase Activities through Acetylation
Luo, Y., Jian, W., Stavreva, D. A., Fu, X., Hager, G. L., Bungert, J., Huang, S., & Qiu, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.038356 · Cited by 80
Epigenetic mechanisms regulate stage differentiation in the minimized protozoan Giardia lamblia
Sonda, S., Morf, L., Bottová, I., Baetschmann, H., Rehrauer, H., Caflisch, A., Hakimi, M., & Hehl, A. B. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07062.x · Cited by 82
Shen, S., Benoy, V., Bergman, J. A., Kalin, J. H., Damião, M. C. F. C. B., Vistoli, G., Haeck, W., Bosch, L. V. D., & Kozikowski, A. P. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00286 · Cited by 81
Sellmer, A., Stangl, H., Beyer, M., Grünstein, E., Leonhardt, M., Pongratz, H., Eichhorn, E., Elz, S., Striegl, B., Jenei‐Lanzl, Z., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01593 · Cited by 80
Development of a Potent and Selective HDAC8 Inhibitor
Ingham, O. J., Paranal, R. M., Smith, W. B., Escobar, R. A., Yueh, H., Snyder, T., Porco, J. A. J., Bradner, J. E., & Beeler, A. B. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00239 · Cited by 79
Pathological Role of HDAC8: Cancer and Beyond
Kim, J. Y., Cho, H., Yoo, J. H., Kim, G. W., Jeon, Y. H., Lee, S. W., & Kwon, S. H. (2022) · Cells · doi:10.3390/cells11193161 · Cited by 79
Moore, J., Bradshaw, E., Seipke, R. F., Hutchings, M. I., & McArthur, M. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-404634-4.00018-8 · Cited by 81
Souto, J. A., Vaz, E., Lepore, I., Pöppler, A., Franci, G., Álvarez, R., Altucci, L., & de Lera, Á. R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100244y · Cited by 80
Wu, R., Hu, P., Wang, S., Cao, Z., & Zhang, Y. (2009) · Journal of Chemical Theory and Computation · doi:10.1021/ct9005322 · Cited by 78
The use of diversity profiling to characterize chemical modulators of the histone deacetylases
Blackwell, L. J., Norris, J. L., Suto, C. M., & Janzen, W. P. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.03.004 · Cited by 79
A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells
Liu, L., Chen, B., Qin, S., Li, S., He, X., Qiu, S., Zhao, W., & Zhao, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.011 · Cited by 78
Zhu, B., Shang, B.-Y., Li, L., & Zhen, Y. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5041 · Cited by 78
Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases
Hildmann, C., Wegener, D., Riester, D., Hempel, R., Schober, A., Merana, J., Giurato, L., Guccione, S., Nielsen, T. K., Ficner, R., et al. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.01.030 · Cited by 78
Charting a Path to Success in Virtual Screening
Forli, S. (2015) · Molecules · doi:10.3390/molecules201018732 · Cited by 81
Nian, H., Bisson, W. H., Dashwood, W. M., Pinto, J. T., & Dashwood, R. H. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp147 · Cited by 77
Gu, W., Cueto, M., Jensen, P. R., Fenical, W., & Silverman, R. B. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.04.025 · Cited by 77
An Unexpected Example of Protein‐Templated Click Chemistry
Suzuki, T., Ota, Y., Kasuya, Y., Mutsuga, M., KAWAMURA, Y., Tsumoto, H., Nakagawa, H., Finn, M. G., & Miyata, N. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201002205 · Cited by 76
Vanaja, G. R., Ramulu, H. G., & Kalle, A. M. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0231-4 · Cited by 76
Deacetylase Inhibitors Dissociate the Histone-Targeting ING2 Subunit from the Sin3 Complex
Smith, K. T., Martin‐Brown, S., Florens, L. A., Washburn, M. P., & Workman, J. L. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.12.010 · Cited by 75
Metabolism as a key to histone deacetylase inhibition
Rajendran, P., Williams, D. E., Ho, E., & Dashwood, R. H. (2011) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2011.557713 · Cited by 76
Targeting of HDAC8 and investigational inhibitors in neuroblastoma
Oehme, I., Deubzer, H. E., Lodrini, M., Milde, T., & Witt, O. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241658 · Cited by 75
Sleiman, S. F., Basso, M., Mahishi, L., Kozikowski, A. P., Donohoe, M. E., Langley, B. C., & Ratan, R. R. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902810345 · Cited by 77
Chen, C., Yu, K., Yan, Q., Xing, C., Chen, Y., Yan, Z., Shi, Y., Zhao, K.-W., & Gao, S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt070 · Cited by 75
Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups
Li, Y., Wang, F., Chen, X., Wang, J., Zhao, Y., Li, Y., & He, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190122144949 · Cited by 80
Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8
Porter, N. J., & Christianson, D. W. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00330 · Cited by 73
Evolution of the arginase fold and functional diversity
Dowling, D., Costanzo, L. D., Gennadios, H. A., & Christianson, D. W. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7554-z · Cited by 75
Innovative Strategies for Selective Inhibition of Histone Deacetylases
Maolanon, A. R., Madsen, A. S., & Olsen, C. A. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.011 · Cited by 72
Maiti, A., Qi, Q., Peng, X., Yan, L., Takabe, K., & Hait, N. C. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4796 · Cited by 72
Rodrigues, D. A., Pinheiro, P. D. S. M., Sagrillo, F. S., Bolognesi, M. L., & Fraga, C. A. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21701 · Cited by 73
Zinc Binding in HDAC Inhibitors: A DFT Study
Wang, D., Helquist, P. M., & Wiest, O. (2007) · The Journal of Organic Chemistry · doi:10.1021/jo070739s · Cited by 72
Schäfer, S., Saunders, L. R., Eliseeva, E. D., Velena, A., Jung, M., Schwienhorst, A., Strasser, A., Dickmanns, A., Ficner, R., Schlimme, S., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.092 · Cited by 71
Expression, purification, assay, and crystal structure of perdeuterated human arginase I
Costanzo, L. D., Moulin, M., Haertlein, M., Meilleur, F., & Christianson, D. W. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.04.036 · Cited by 71
Halder, A. K., Mallick, S., Shikha, D., Saha, A., Saha, K. D., & Jha, T. (2015) · RSC Advances · doi:10.1039/c5ra12606a · Cited by 71
Amin, S. A., Adhikari, N., & Jha, T. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.002 · Cited by 71
Andreoli, F., Barbosa, A. J. M., Parenti, M. D., & Río, A. D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804581918 · Cited by 68
General Base–General Acid Catalysis in Human Histone Deacetylase 8
Gantt, S. M. L., Decroos, C., Lee, M. S., Gullett, L. E., Bowman, C. M., Christianson, D. W., & Fierke, C. A. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01327 · Cited by 67
A series of novel, potent, and selective histone deacetylase inhibitors
JONES, P. G., Altamura, S., Chakravarty, P. K., Cecchetti, O., Francesco, R. D., Gallinari, P., Ingenito, R., Meinke, P. T., Petrocchi, A., Rowley, M., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.002 · Cited by 67
Self-citationTargeting class I histone deacetylases in cancer therapy
Delcuve, G. P., Khan, D. H., & Davie, J. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.729042 · Cited by 66
Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
Auzzas, L., Larsson, A., Matera, R., Baraldi, A., Deschênes-Simard, B., Giannini, G., Cabri, W., Battistuzzi, G., Gallo, G., Ciacci, A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101092u · Cited by 65
Non-Peptide Macrocyclic Histone Deacetylase Inhibitors
Oyelere, A. K., Chen, P. C., Guerrant, W., Mwakwari, S. C., Hood, R., Zhang, Y., & Fan, Y. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801128g · Cited by 64
The class I histone deacetylases of the platyhelminth parasite Schistosoma mansoni
Oger, F., Dubois, F., Caby, S., Noël, C. J., Cornette, J., Bertin, B., Capron, M., & Pierce, R. J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.10.090 · Cited by 63
New perspectives of valproic acid in clinical practice
Činčárová, L., Zdráhal, Z., & Fajkus, J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.853037 · Cited by 64
Azetidinones as Zinc‐Binding Groups to Design Selective HDAC8 Inhibitors
Galletti, P., Quintavalla, A., Ventrici, C., Giannini, G., Cabri, W., Penco, S., Gallo, G., Vincenti, S., & Giacomini, D. (2009) · ChemMedChem · doi:10.1002/cmdc.200900309 · Cited by 63
Tabackman, A. A., Frankson, R., Marsan, E. S., Perry, K., & Cole, K. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2016.06.023 · Cited by 64
Kahnberg, P., Lucke, A. J., Glenn, M. P., Boyle, G. M., Tyndall, J. D. A., Parsons, P. G., & Fairlie, D. P. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050214x · Cited by 63
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
New patented histone deacetylase inhibitors
Wang, H., & Dymock, B. W. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903393789 · Cited by 62
Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands
Wood, T. E., Dalili, S., Simpson, C. D., Sukhai, M. A., Hurren, R., Anyiwe, K., Mao, X., Suárez, F., Gronda, M., Eberhard, Y., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0495 · Cited by 62
Ballante, F., & Marshall, G. R. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00603 · Cited by 63
Identification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors
Tang, G., Wong, J. C., Zhang, W., Wang, Z., Zhang, N., Peng, Z., Zhang, Z., Rong, Y., Li, S., Zhang, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5008962 · Cited by 62
Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling
Chen, Y., Jiang, Y., Zhou, J., Yu, Q., & You, Q. (2007) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2007.10.007 · Cited by 61
Inhibition and Mechanism of HDAC8 Revisited
Chen, K., Zhang, X., Wu, Y., & Wiest, O. (2014) · Journal of the American Chemical Society · doi:10.1021/ja501548p · Cited by 61
Lopez, G., Bill, K. L. J., Bid, H. K., Braggio, D., Constantino, D., Prudner, B., Zewdu, A., Batte, K., Lev, D., & Pollock, R. E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133302 · Cited by 60
Jeannot, V., Busser, B., Brambilla, E. M., Wislez, M., Robin, B., Cadranel, J. L., Coll, J., & Hurbin, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28594 · Cited by 60
Metadata
- Authors
- Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., Steinkühler, C., & Di Marco, S.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Department of Biochemistry, Istituto di Ricerche di Biologia Molecolare P. Angeletti, 00040 Pomezia, Rome, Italy; and Department of Medicinal Chemistry, Merck and Company, Inc., Rahway, NJ 07065
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-10-11
- Volume
- 101
- Issue
- 42
- Pages
- 15064-15069
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC524051
- OpenAlex
- W2078454854
- Semantic Scholar
- 03c10a313fe9a3fe15c2052dfba5f2319155ebba
- Cited by
- 638
- References
- 23
- Citations by year
- 2026: 19 · 2025: 13 · 2024: 25 · 2023: 17 · 2022: 18 · 2021: 19 · 2020: 23 · 2019: 27 · 2018: 20 · 2017: 27 · 2016: 34 · 2015: 37 · 2014: 30 · 2013: 34 · 2012: 40
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- HDAC8, histone deacetylase, hydroxamate inhibitors, zinc metalloenzyme, crystal structure, potassium ions, active site, anticancer agents, histone deacetylase inhibitors, tumor cell proliferation, RNAi knockdown
- MeSH terms
- Amino Acid Sequence, Antineoplastic Agents, Circular Dichroism, Enzyme Inhibitors, Histone Deacetylases, Humans, Hydroxamic Acids, Models, Molecular, Molecular Sequence Data, Potassium, Protein Conformation, Recombinant Proteins, Repressor Proteins, Zinc, Drug Design, Sequence Homology, Amino Acid, Crystallography, X-Ray, Catalytic Domain, RNA Interference, Cell Line, Tumor, Histone Deacetylase Inhibitors, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
